1. Early Viral Suppression Predicting Long-term Treatment Success Among HIV Patients Commencing NNRTI-based Antiretroviral Therapy
- Author
-
Lamom Boonpok, Wirach Maek-a-nantawat, Chayaporn Japrasert, Benjaluck Phonrat, Sirima Tepsupa, Aung Naing Soe, and Somsit Tansuphasawadikul
- Subjects
medicine.medical_specialty ,Reverse-transcriptase inhibitor ,business.industry ,virus diseases ,Omics ,medicine.disease ,Antiretroviral therapy ,Virology ,Infectious Diseases ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Pill ,medicine ,Lost to follow-up ,business ,Viral load ,Lipoatrophy ,medicine.drug - Abstract
Non-nucleoside reverse transcriptase inhibitor (NNRTI) -based antiretroviral therapy (ART) regimens have been recommended and widely used in resource-limited settings because of their reliable effi cacy, low pill burden, and low cost. This study sought to determine outcomes and toxicities of NNRTI-based ART over a period of 208 weeks. A total of 244 HIV/AIDS Thai patients with a mean (±SD) age of 36 (±8.1) years initiated NNRTI-based ART in 2004. The median (inter-quartile range) baseline CD4 cell counts and HIV RNA levels were 34 (13-101) cells/mm3 and 5.4 (4.96-5.79) log copies/ml, respectively. At week 208, 84.6% of patients achieved HIV RNA loads
- Published
- 2010
- Full Text
- View/download PDF